Validation of a Diagnostic Score for Encephalitis to Assess the Risk of Autoimmune Origin
NCT ID: NCT05953974
Last Updated: 2023-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
350 participants
OBSERVATIONAL
2023-02-01
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
NCT05728931
Predicting Functional Outcome and Response to Therapy of Anti-NMDAR Encephalitis at Diagnosis
NCT06023160
Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus
NCT05880121
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
NCT06412614
Prediction of Outcome of Lupus Nephritis
NCT02403115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NMDAr patients
Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :
\- Anti NMDAr
Clinical score of Granillo and al.
Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
LGI1 patients
Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :
\- Anti LGI1
Clinical score of Granillo and al.
Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
CASPR2 patients
Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :
\- Anti CASPR2
Clinical score of Granillo and al.
Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
GABAb patients
Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :
\- Anti GABAb
Clinical score of Granillo and al.
Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
GAD patients
Patients \> or = 18 years old presenting with auto-immune encephalitis, defined according to the Graus criteria, with neuronal antibodies :
\- Anti GAD
Clinical score of Granillo and al.
Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical score of Granillo and al.
Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a definite auto-immune encephalitis (Graus and al. 2016)
Exclusion Criteria
* Patient with several antibodies
* Opposition
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL23_0627
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.